HBM Healthcare Investments finances companies related to human medicine, biotechnology, medical technology, and diagnostics sectors.
As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unquoted emerging companies, with two-thirds are invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Mar 7, 2022
Karius
|
Series B | — | Biotechnology | — |
Dec 7, 2021
Freenome
|
Series D | $300M | Biotechnology | — |
Jan 20, 2021
Karius
|
Series B | — | Biotechnology | — |
Dec 29, 2020
Instil Bio
|
Series C | — | Biotechnology | — |
Sep 28, 2020
BioShin
|
Series A | $60M | Biotechnology | — |